Danicopan Emerging Drug Insight and Market Forecast - 2032

“"Danicopan Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about danicopan for paroxysmal nocturnal hemoglobinuria (PNH) in the seven major markets. A detailed picture of the danicopan for PNH in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the danicopan for PNH. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the danicopan market forecast analysis for PNH in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in PNH.

Drug Summary:

ALXN2040 (also known as danicopan) is an investigational, first-in-class, oral proximal factor D inhibitor developed by Achillion, a wholly owned subsidiary of Alexion. Factor D (FD), a serine protease, catalyzes the cleavage of complement factor B into Ba and Bb, which allows for the formation of the AP C3 convertase. By inhibiting FD, danicopan, blocks C3 convertase formation, the control point for AP activation, and the amplification of all pathways. This leads to the inhibition of C3 cleavage, C3 fragment deposition, terminal pathway activation, and MAC formation.

The drug has already received Breakthrough Therapy Designation (BTD) and Orphan Drug Designation (ODD) by the FDA and PRIME designation and ODD by the EMA. Phase III development is currently being initiated for danicopan as an add-on therapy for PNH patients with extravascular hemolysis (EVH). Besides, the company is conducting Phase II studies to determine the effectiveness of ACH-0144471 in patients with PNH who have an inadequate response to eculizumab monotherapy.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the danicopan description, mechanism of action, dosage and administration, research and development activities in paroxysmal nocturnal hemoglobinuria (PNH).
• Elaborated details on danicopan regulatory milestones and other development activities have been provided in this report.
• The report also highlights the danicopan research and development activities in PNH across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around danicopan.
• The report contains forecasted sales of danicopan for PNH till 2032.
• Comprehensive coverage of the late-stage emerging therapies for PNH.
• The report also features the SWOT analysis with analyst views for danicopan in PNH.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Danicopan Analytical Perspective by DelveInsight

• In-depth Danicopan Market Assessment

This report provides a detailed market assessment of danicopan for paroxysmal nocturnal hemoglobinuria (PNH) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• Danicopan Clinical Assessment

The report provides the clinical trials information of danicopan for PNH covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for paroxysmal nocturnal hemoglobinuria (PNH) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence danicopan dominance.
• Other emerging products for PNH are expected to give tough market competition to danicopan and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of danicopan in PNH.
• Our in-depth analysis of the forecasted sales data of danicopan from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the danicopan in PNH.

Key Questions

• What is the product type, route of administration and mechanism of action of danicopan?
• What is the clinical trial status of the study related to danicopan in paroxysmal nocturnal hemoglobinuria (PNH) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the danicopan development?
• What are the key designations that have been granted to danicopan for PNH?
• What is the forecasted market scenario of danicopan for PNH?
• What are the forecasted sales of danicopan in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to danicopan for PNH?
• Which are the late-stage emerging therapies under development for the treatment of PNH?